--- title: "Sex‐Specific Outcomes and Treatment Responses in Elderly Patients With Heart Failure With Preserved Ejection Fraction: A Comprehensive Single‐Center Retrospective Study" id: "journal-of-the-american-heart-association-10-sex-specific-outcomes-and-treatment-responses-in-elderly-patients-with-heart" canonical_url: "https://medichelpline.com/clinical-feed/journal-of-the-american-heart-association-10-sex-specific-outcomes-and-treatment-responses-in-elderly-patients-with-heart" content_type: "clinical_feed_article" specialty: "Cardiology" source_name: "Journal of the American Heart Association" source_url: "https://www.ahajournals.org/doi/abs/10.1161/JAHA.125.046799?ai=sg&mi=3&af=R" published_at: "2026-06-09T11:50:19.000Z" evidence_level: "Journal Feed" license: "CC-BY-NC-4.0 / Informational Use" --- # Sex‐Specific Outcomes and Treatment Responses in Elderly Patients With Heart Failure With Preserved Ejection Fraction: A Comprehensive Single‐Center Retrospective Study ## Provenance & Clinical Metadata - **Canonical URL:** https://medichelpline.com/clinical-feed/journal-of-the-american-heart-association-10-sex-specific-outcomes-and-treatment-responses-in-elderly-patients-with-heart - **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md) - **Primary Source:** Journal of the American Heart Association - **Source URL:** [Original Journal Publication](https://www.ahajournals.org/doi/abs/10.1161/JAHA.125.046799?ai=sg&mi=3&af=R) - **Published At:** 2026-06-09T11:50:19.000Z - **Evidence Rating:** Journal Feed ## Executive GIST (TL;DR) Journal of the American Heart Association, Volume 15, Issue 12 , June 16, 2026. BackgroundHeart failure with preserved ejection fraction (HFpEF) disproportionately affects elderly women, with potential contributions from sex‐specific hormonal and physiological factors. We aimed to evaluate sex‐specific prognostic differences, comorbidity impacts, and guideline‐directed medical therapy effects in elderly patients with HFpEF.MethodsRetrospective analysis of 603 patients (age ≥60 years, male: 51.6%, mean age: 79.10±9.19 years) newly diagnosed with HFpEF at Huadong Hospital, Fudan University (from July 2019 to June 2024) with follow‐up through December 2024. The primary outcome was all‐cause mortality.ResultsThe overall mortality rate was 14.2/100 person‐years (women: 15.4 versus men: 13.2). Based on the gender and etiology phenotype classification for HFpEF, patients with types I/IV HFpEF had better survival (10.0/12.4 per 100 person‐years) versus those with types II/III/V (17.1/22.9/24.2 per 100 person‐years). Sex‐specific mortality peaks differed, with men having type V in 30.3/100 person‐years and women having type III in 28.2/100 person‐years. In Cox regression analysis, after adjusting for age, sex, body mass index, and hypertension, type 2 diabetes and stages 4 or 5 chronic kidney disease predicted mortality in men only (chronic kidney disease 4 or 5: hazard ratio [HR], 3.24, type 2 diabetes: HR, 2.34; both adjustedP 0.1). After adjusting for age, body mass index, hypertension, type 2 diabetes, and renal dysfunction, angiotensin receptor neprilysin inhibitors reduced mortality in women (HR, 0.57; adjustedP=0.027), while sodium‐glucose cotransporter‐2 inhibitors reduced mortality in men (HR, 0.25; adjustedP=0.021).ConclusionsMortality patterns, comorbidity impacts, and treatment responses in elderly patients with HFpEF exhibit significant sex disparities. This underscores the need for sex‐tailored management to optimize outcomes. These findings should be interpreted with caution given the retrospective design. ## Clinical Analysis & Structured Key Points Journal of the American Heart Association, Volume 15, Issue 12 , June 16, 2026. BackgroundHeart failure with preserved ejection fraction (HFpEF) disproportionately affects elderly women, with potential contributions from sex‐specific hormonal and physiological factors. We aimed to evaluate sex‐specific prognostic differences, comorbidity impacts, and guideline‐directed medical therapy effects in elderly patients with HFpEF.MethodsRetrospective analysis of 603 patients (age ≥60 years, male: 51.6%, mean age: 79.10±9.19 years) newly diagnosed with HFpEF at Huadong Hospital, Fudan University (from July 2019 to June 2024) with follow‐up through December 2024. The primary outcome was all‐cause mortality.ResultsThe overall mortality rate was 14.2/100 person‐years (women: 15.4 versus men: 13.2). Based on the gender and etiology phenotype classification for HFpEF, patients with types I/IV HFpEF had better survival (10.0/12.4 per 100 person‐years) versus those with types II/III/V (17.1/22.9/24.2 per 100 person‐years). Sex‐specific mortality peaks differed, with men having type V in 30.3/100 person‐years and women having type III in 28.2/100 person‐years. In Cox regression analysis, after adjusting for age, sex, body mass index, and hypertension, type 2 diabetes and stages 4 or 5 chronic kidney disease predicted mortality in men only (chronic kidney disease 4 or 5: hazard ratio [HR], 3.24, type 2 diabetes: HR, 2.34; both adjustedP 0.1). After adjusting for age, body mass index, hypertension, type 2 diabetes, and renal dysfunction, angiotensin receptor neprilysin inhibitors reduced mortality in women (HR, 0.57; adjustedP=0.027), while sodium‐glucose cotransporter‐2 inhibitors reduced mortality in men (HR, 0.25; adjustedP=0.021).ConclusionsMortality patterns, comorbidity impacts, and treatment responses in elderly patients with HFpEF exhibit significant sex disparities. This underscores the need for sex‐tailored management to optimize outcomes. These findings should be interpreted with caution given the retrospective design. ## Related Clinical Research - [Boost Potassium as well as Lower Sodium for Better Blood Pressure Control](https://medichelpline.com/clinical-feed/medical-news-today-0-for-better-blood-pressure-control-don-t-just-lower-salt-also-boost-potassium.md) - [Adherence to Medications, Lifestyle Advice, and Self‑Monitoring for Type 2 Diabetes and Hypertensi](https://medichelpline.com/clinical-feed/plos-medicine-0-adherence-to-medications-lifestyle-advice-and-self-monitoring-for-type-2.md) - [Lifestyle Changes May Help Prevent Multimorbidity In Prediabetes](https://medichelpline.com/clinical-feed/medical-news-today-23-diet-weight-loss-and-150-minutes-of-exercise-may-protect-against-chronic.md) - [Moving Forward: The Future of GLP-1 Therapies](https://medichelpline.com/clinical-feed/endocrine-news-18-moving-forward-the-future-of-glp-1-therapies.md) - [Long-term cardiovascular risk after assisted reproductive technology and infertility: nationwide c](https://medichelpline.com/clinical-feed/plos-medicine-0-long-term-risk-of-cardiovascular-disease-after-assisted-reproductive-technology.md) ## Navigation - [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md) - [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md) ## Medical & Regulatory Disclaimer > [!CAUTION] > MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations. > Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.